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Chalcones in Dermatology
Jumina, Harizal and Yehezkiel Steven Kurniawan
Abstract
The human skin is pivotal for protecting the body from various stresses and 
diseases, regulating several physiological aspects, and sensing any signal changes 
around the environment. To work and function optimally, the skin should be 
protected and cared regularly by using some treatments. Chalcone, as a privileged 
structure, exhibits wide and unique bioactivities related to several skin disorders 
such as in preventing and treating pigmentation disorders (melasma and vitiligo), 
cutaneous leishmaniasis, rashes (acne vulgaris, seborrheic dermatitis and dandruff, 
psoriasis and atopic dermatitis), and rosacea. In this chapter, the role of chalcone 
derivatives in treating several skin disorders as mentioned above is discussed to 
provide a brief and comprehensive perspective regarding the role of chalcone in 
dermatology including in vitro, preclinical, and clinical assays.
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1. Introduction
In the human body, the skin is the outermost and largest organ with three basic 
functions, i.e. protecting from various stresses and hazards, regulating some physi-
ological aspects, and sensing any conditional changes in the environment. While 
conducting its functions, the skin works with other internal systems and forms 
a rigid network with nervous, immune, and endocrine systems [1]. On the other 
hand, the skin also interacts with the environment around [2] such as microorgan-
isms living on the skin surface [3] to maintain the function of the human body. Any 
imbalances between these factors often lead to various multifactorial skin disorders 
[4]. Based on their main cause, skin disorders can be classified into six groups 
including tumor and cancer, trauma, pigmentation disorders, microbial (viral, 
bacterial, fungal, and parasitic) infections, rashes, and miscellaneous conditions 
[5]. Therefore, treatment of skin disorders requires systematic attention in the 
medical field.
The treatment of skin disorders is usually conducted in topical, systematic, or 
combinatorial modes using bioactive compounds to relieve any formed defects in 
nervous, immune, and endocrine systems. Various bioactive compounds have been 
evaluated through a long clinical assay [6]. In the development process of these 
compounds, many parameters should be considered such as economical aspect, 
bioavailability, stability, toxicity, and metabolism of drug molecules in both topical 
and systematic therapies [7].
Chalcone is a class of organic compounds with 1,3-diaryl-2-propen-1-one 
(Figure 1) as the backbone structure that is obtained either through an isolation 
and purification process from natural samples [8], semisynthesis process from 
existing natural products [9], or total synthesis process [10]. Chalcone is considered 
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as privileged scaffold since it exhibits broad biological activities [10]. Many pieces 
of study have used chalcone as a lead compound to find more potent drugs for 
diseases due to the ease and convenience in synthesizing and functionalizing 
chalcone structure. In treating skin disorders, the efficacy of chalcone derivatives is 
related to several biological activities including antioxidant [11], anti-inflammation 
[12], immunomodulation [13], anti-angiogenesis [14], antimicrobial [15], and 
enzyme modulator [16]. The usage of chalcone derivatives in dermatology has been 
developed over the past several years to obtain the most active ingredient in either 
for maintaining skin health or treating skin disorders. Licochalcone A, isoliquiriti-
genin, and xanthohumol are examples of well-known chalcone derivatives with low 
toxicity and side effects on treating skin disorders and disease. In this chapter, these 
applications are described and discussed to provide a broad and comprehensive 
perspective regarding the role of chalcones in the dermatology field.
2. Dangerous impacts of ultraviolet irradiation
The ultraviolet (UV) light is the electromagnetic radiation with a wavelength 
range from 200 to 400 nm. In general, based on the wavelength range, UV radiation 
is divided into four regions including UVC, UVB, UVA2, and UVA1 at 200–280, 
280–320, 320–340, and 340–400 nm, respectively. This hazardous radiation causes 
various acute and chronic negative effects on the human skin. Clinical manifesta-
tions that occur usually depend on the wavelength and intensity of UV radiation, 
part of the body exposed, and type of skin (based on Fitzpatrick’s classification of 
skin). Acute effects of UV radiations, in general, involve various forms of inflam-
mations such as erythema, local immunosuppression, phototanning, and epidermis 
thickening [17]. Mechanistically, acute effects are initiated by suitable interactions 
between several chromophores (either on the epidermis or dermis layers) and UV 
irradiation [18]. These interactions trigger the structural changes that modulate 
various biochemical and immunological processes [19] such as releasing several 
pro-inflammatory cytokines, damaging various cell biomolecules [20], generating 
various reactive oxygen species (ROS) [21], and producing several inflammatory 
mediators such as prostaglandins, histamine, and leukotrienes [22, 23]. Meanwhile, 
chronic effects usually lead to photoadaptation or photoprotection effects through 
the formation of photoaging, immunosuppression, and photocarcinogenesis. [17].
2.1 Chalcones as sunscreen active ingredients
Chalcone has been found as one of the bioactive compounds that is able to 
reduce negative effects from UV radiation such as hesperidin methyl chalcone, 
licochalcone A, etc. Chalcones as antioxidant and anti-inflammatory agents are 
Figure 1. 
Backbone structure of chalcones.
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used in topical or systemic methods, while the sunscreen agent is used in topical 
applications. In general, the sunscreen activity of chalcones is generated by high UV 
absorbance on the UVB-UVA region [24], which corresponds to n → π* and π → π* 
electronic transition from HOMO to LUMO energy levels in chalcones’ conjugated 
electronic system. The absorbance region of chalcones can be shifted by introduc-
ing electron-donor substituents (bathochromic shift) or electron-withdrawing 
substituents (hypsochromic shift) in both of the chalcone aromatic rings. However, 
the effects of these groups are more significant if present in A ring compared to B 
ring [25].
The main problem in using chalcone derivatives as sunscreen active compound 
is relatively poor photostability and transformations into various by-products 
[26–28]. Several reports have investigated the utilization of chalcone derivatives as 
sunscreen active compounds and also prepared sunscreen formulations with high 
compatibility on the skin. However, the photostability of chalcone derivatives used 
has not been evaluated yet [25, 26].
2.2 Chalcones as photoprotective agents
Several chalcones exhibit strong protection on UV-induced deleterious effects 
such as trans-chalcone, butein, monspermoside, licochalcone A, phloretin, and 
hesperidin derivatives. Unsubstituted trans-chalcones showed a potential activity 
in reducing inflammation effect and oxidative stress in mice [27, 28]. A formula-
tion containing 1% unsubstituted trans-chalcone has been applied to protect the 
skin from UVB radiation by inhibiting inflammation through reducing tumor 
necrosis factor alpha (TNF-α) levels and improving antioxidant and detoxification 
systems through enhancing heme oxygenase 1 (HO-1) and nuclear factor erythroid 
2-related factor 2 (Nrf2) messenger ribonucleic acid (mRNA) expressions [28]. 
Systemic administration of trans-chalcone could inhibit UVB-induced skin inflam-
mation and prevented oxidative stress by targeting nicotinamide adenine dinucleo-
tide phosphate H (NADPH) oxidase and cytokine production [27]. Butein and 
monspermoside compounds were also used as photostabilizer for UVA-absorbing 
compounds such as dibenzoylmethane [29].
Licochalcone A, isolated from Glycyrrhiza inflata, is the most well-studied 
chalcone derivative related to its activity as UV photoprotector. Either in vitro or 
in vivo studies showed that licochalcone A had a strong protective effect against 
UVB-induced oxidative stress and inflammation. Licochalcone A attenuated UVB-
induced inflammation by inhibiting prostaglandin E2 (PGE2), cyclooxygenase 
(COX-2), lipoxygenase, nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB), and Nrf2 [30–32], while in vivo assay showed that topical for-
mulation containing licochalcone A caused a significant reduction in UV-induced 
erythema, irritation, and oxidative process in the skin [31–33].
Similar to their flavanone analog, hesperidin [34], hesperidin methyl chalcone, 
and hydrolyzed methylhesperidin compounds as semisynthetic products also 
exhibit high UV protective effect. Topical and systematic administration of hes-
peridin methyl chalcone in hairless mice inhibited UVB-induced oxidative stress 
by reducing free radicals and ROS, enhanced endogenous antioxidant systems, 
and inhibited inflammation by reducing the production of cytokines [35]. The 
hydrolysis product of methylhesperidin, 4′,6′-dihydroxy-3,4,2′-trimethoxychalcone 
and 4′-hydroxy-3,4,2′,6′-tetramethoxychalcone compounds, also induced cyto-
protective gene expression and reduced oxidative stress by promoting Nrf2 nuclear 
translocation and antioxidant response element (ARE) luciferase activity in UVB-
irradiated keratinocytes [36].
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Phloretin is a natural dihydrochalcone that exhibited a strong inhibition of 
several matrix metalloproteinases. The isolated 3-hydroxyphloretin and phloretin 
from Malus doumeri var. formosana showed high inhibition of MMP-1 production 
in fibroblast cells [37]. A combination of phloretin, ferulic acid, and vitamin C 
as antioxidants had a high protective effect on UV damage in the human skin by 
preventing erythema formation and inhibiting MMP-9 and thymine dimerization 
reaction. In this case, phloretin acted as an antioxidant and synergized with other 
antioxidants by stabilizing and enhancing the bioavailability of ferulic acid and 
vitamin C in the skin [38].
3. Pigmentation disorders
Melanogenesis is a complex process of production and distribution of melanin 
by melanocytes. In this process, melanins (in form of eumelanin, pheomelanin, 
or trichochrome) are synthesized and stored in melanosomes (an organelle in 
melanocytes) and then transported to nearby keratinocytes to act as photoprotec-
tor in the skin and lead to chronic pigmentations [39]. The synthesis of melanin 
involves several reaction steps and is catalyzed by phenylalanine hydroxylase 
(PAH), tyrosinase (TYR), tyrosine hydroxylase isoform I (THI), tyrosinase-
related protein 1 (TRYP1), and tyrosinase-related protein 2 (TRYP2) [40] 
enzymes. The rate-determining step of this process is hydroxylation of L-tyrosine 
to L-dopaquinone catalyzed by tyrosinase enzyme [41]. The final products of this 
process include black-brown eumelanin, yellow-reddish brown pheomelanin, and 
trichochrome [42].
There are many internal (endocrine, immune, inflammatory, and central 
nervous systems) and external (ultraviolet radiation and drugs) factors that affect 
the melanogenesis process [41]. Any disruptions from these factors will cause 
different types of pigmentation disorders including various skin conditions with 
strange melanocyte density, melanin concentration, or both that change pigmenta-
tions in the skin [43]. In general, pigmentation disorders can be divided into two 
main groups including hyperpigmentation and hypopigmentation that related to 
the amount of changes of normal melanin pigmentation, respectively. Both of these 
groups include several diseases with different clinical manifestations, but the most 
common forms of these are melasma (hyperpigmentations) and vitiligo (hypopig-
mentations) [42, 43].
3.1 Melasma
Melasma is a multifactorial skin disease indicated by the presence of sym-
metrical hyperpigmented area in a certain part of the face including centrofacial, 
malar, and mandibular parts. This disease is affected by UV, visible, and infrared 
exposure, by inducing reactive oxygen species and promoting melanogenesis [44], 
hormonal conditions [45], and genetics [46]. Chalcone derivatives are extensively 
used in medical therapy as photoprotective described in Sections 2.1 and 2.2, and 
hypopigmenting agents. Various studies showed that either natural or synthetic 
chalcones exhibited strong activity in inhibiting cellular tyrosinase and reducing 
cellular melanin formation [47]. However, the action mode of chalcone derivatives 
in this study is unknown since most of these studies used mushroom tyrosinase 
that is different from human tyrosinase [48]. Other studies conducted by Kim 
and coworkers showed similar results with additional parameters. In these stud-
ies, chalcones containing cyclohexylmethoxy group not only attenuated cellular 
melanin production and tyrosinase activity, but also reduced the expressions of 
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several melanogenesis-related genes (transcriptional activity of tyrosinase and 
microphthalmia-associated transcription factor/MITF) and proteins (TRP1, TRP2, 
and MITF) [49, 50].
Table 1 shows several in vitro assays that use Murine B16 melanoma cell lines 
(B16F10), melanoma cells, and human melanocyte (G361) cells in determining 
chalcone derivatives’ efficacy for hypopigmenting agent. In vivo studies also 
showed that licochalcone A and isoliquiritigenin-containing licorice extract cream 
can improve melasma and increase skin brightness [51]. Loading the licorice extract 
into solid lipid nanoparticles has been formulated and applied in a clinical trial for 
melisma [52].
3.2 Vitiligo
Vitiligo is an acute skin disease characterized by unilaterally distributed depig-
mented areas in the skin due to the systematic degradation of melanocytes [56]. 
The mechanism triggering this disease has not completely elucidated yet; however, 
there are several theories proposed to explain it including genetics (mutations of 
certain genes cause autoimmunity) [57], autoimmunity (instable melanocytes 
induce immune system activation), oxidative stress (endogenous and exogenous 
stress-induced reactive oxygen species that cause internal damage of melanocytes) 
Chalcone derivatives Source Types 
of cells
Effects (ref.)*
Isoliquiritigenin Glycyrrhiza 
glabra L.
G361 ↓Cellular melanin formation 
(IC50 4.73 μg/mL) [53]
2,4,3′,4′-Tetrahydroxychalcone Synthetic G361 (M = 5 μM) ↓cellular melanin 
content (62.5%) [54]
2,4,2′,4′-Tetrahydroxychalcone Synthetic G361 (M = 5 μM) ↓cellular melanin 
content (55.0%) [54]
3-Hydroxyphloretin Malus 
doumeri var. 
formosana
HEMn** (M = 100 μM) ↓cellular 
tyrosinase (80.5%) and 
cellular melanin content 
(18.3%) [55]
2′-Cyclohexylmethoxy-6′-hydroxy-4-
hydroxymethylchalcone
Synthetic B16F10 ↓Cellular melanin production 
(IC50 = 6.2 μM) and 
cellular tyrosinase activity 
(IC50 = 6.8 μM); ↓TRP1, 
TRP2, and MITF expression; 
↓transcriptional activity of 
tyrosinase (IC50 = 6.0 μM) and 
MIRF (IC50 = 5.8 μM) [49]
4-Acetamido-2′-
cyclohexylmethoxychalcone
Synthetic B16F10 ↓Cellular melanin production 
(IC50 = 0.54 μM) and 
cellular tyrosinase activity; 
↓MITF, TRP1 and TRP2 
expression; ↓phosphorylation 
of ERK1/ERK2 and CREB; 
↓transcriptional activity of 
MITF and CRE [50]
*IC50, half maximal inhibitory concentration; ERK1/ERK2, extracellularly regulated kinase 1 and 2; CREB, cyclic 
adenosine monophosphate (cAMP) response element-binding protein.
**HEMn: Primary skin melanocyte cells from neonatal foreskin.
Table 1. 
Chalcone derivatives activities in inhibiting cellular melanogenesis.
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[58], melanocyte growth and defective melanocyte adhesion (repeated pressure 
and friction cause detachment of melanocytes to surrounding structures) [59], viral 
infections (certain viruses cause vitiligo) [60], and neural mechanism (neuropep-
tides elevate in vitiligo lesions) [61].
Improvement of skin appearance in vitiligo can be approached either by pigmen-
tation or depigmentation. Chalcone derivatives are able to act as hypopigmenting 
(as described in Section 4.1) and hyperpigmenting agents. Several chalcone deriva-
tives acted as hyperpigmenting agent by activating tyrosinase enzyme and elevat-
ing melanin production (Table 2). The presence of certain electron-withdrawing 
substituents such as halogen and trifluoromethyl substituents on the chalcone 
structure exhibited a significant effect in activating tyrosinase [62]. Chalcones also 
showed strong absorption in UV regions with low toxicity and have been formu-
lated as broad-spectrum sunscreen protecting the affected skin from UV radiations 
and photofilter used in narrow-band UVB (NB-UVB) phototherapy [63].
4. Cutaneous leishmaniasis
Leishmaniasis is one of the vector-borne diseases generated by Leishmania 
spp. protozoans and transmitted to mammals through infected female sandflies 
(Phlebotomus and Lutzomyia) [66]. In general, certain Leishmania species can 
cause different clinical features with different degree of severity as the result of 
the interplay between Leishmania species characteristics, biological vector, and the 
responses of host immune system [67]. In this section, the explanation is focused on 
the cutaneous leishmaniasis as the most well-known form [68].
Cutaneous leishmaniasis is identified by the presence of skin lesions (ulcers) 
in the biting spot of Leishmania spp.-infected sandfly. Almost all pathogenic 
Leishmania spp. could cause cutaneous leishmaniasis (18 from 20 species) [69] with 
24 species of Phlebotomus spp. and 40 species of Lutzomyia spp. acting as a vector or 
potential vector [70]. At first, after biting by the infected female sandfly, the spot 
will form small erythema developing into a papule and then a nodule and ulcerate 
to become skin lesion. In the human body, promastigotes of Leishmania parasites 
injected by sandfly will be phagocytosed by macrophages [71]. Promastigotes 
manipulate macrophages to develop and multiply promastigote into amastigotes 
that infect another sandfly by biting infected human [72]. These processes cause 
Chalcone derivatives Source Types 
of cells
Effects (ref.)
Chalcone-containing Kaliziri extract Vernonia 
anthelmintica (L.) 
Willd.
B16F10 ↑Tyrosinase, TRP-1, TRP-2, 
and MITF expression [64]
4′-(3-(3,4-Difluorophenyl)isoxazol-
5-yl)methoxychalcone
Synthetic B16F10 (M = 50 μM) ↑cellular 
melanin content (463%) [62]
4-(3-(2,3-Dihydrobenzo[b]
[1,4]dioxin-6-yl)isoxazol-5-yl)
methoxychalcone
Synthetic B16F10 (M = 50 μM) ↑cellular 
melanin content (438%) [62]
4′-Methoxy-4-
dimethylaminochalcone
Synthetic B16F10 (M = 40 μM) ↑cellular 
melanin content (75%); 
↑cellular tyrosinase activity 
(30%) [65]
Table 2. 
Chalcone derivatives’ activities in activating cellular melanogenesis.
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Species Compounds Source Activity (IC50) and mechanism
*
L. major Licochalcone A** Glycyrrhiza 
uralensis
↓Intracellular amastigoten 
(0.5 μg/mL) by damaging 
amastigote mitochondria and 
disturbing its function [73] and 
inhibiting fumarate  
reductase [74]
L. amazonensis 4-Fluoro-2′-hydroxy-4′,6′-
dimethoxychalcone**
Synthetic ↓Promastigote (0.8 μM), 
↓intracellular amastigoten 
(4.3 μM). Mechanism is not 
related to the inhibition of 
fumarate reductase [78]
3′,4′,5′-Trimethoxy-
3-nitrochalcone in 
nanoemulsions
Synthetic ↓Intracellular amastigoten 
(0.32 μM) [79]
trans-chalcone Synthetic ↓Axenic amastigoten (10.3 μM), 
↓promastigote (10.3 μM) 
by ↑ROS production and 
↓mitochondrial integrity, 
phosphatidylserine exposure, 
and damaging the membrane.
Immunomodulator by ↓ TNF-α, 
TGF-β, IL-10, ROS and NO, 
↑ Nrf2, heme oxygenase, and 
ferritin [80]
2′,4′-Dihydroxychalcone** Synthetic ↓Promastigotes (0.4 μM) by 
inhibiting glycerol-3-phosphate 
dehydrogenase [77]
Lonchocarpine/4-
hydroxylonchocarpine 
(3:1)**
Dorstenia 
mannii
↓Intracellular amastigotes 
(6.64 μg/mL). Activity comes 
from synergistic effect from two 
compounds [81]
2′-Hydroxy-4′,6′-
dimethoxy-3-nitrochalcone
Synthetic ↓Intracellular amastigotes (7.2 μg/
mL) [82]
L. braziliensis trans-chalcone Synthetic ↓Promastigotes (1.58 μM) [83]
4-Methoxy-3-(N-
phenylsulfamoyl)chalcone
Synthetic ↓Promastigotes (3.50 μM) [84]
3-Chloro-2′,4′,6′-
trimethoxychalcone
Synthetic ↓Promastigotes (2.70 μM) [85]
L. infantum (E)-3-(5-nitrofuran-2-yl)-1-
(4-(piperidin-1-yl)phenyl)
prop-2-en-1-one**
Synthetic ↓Amastigotes (6.2 μM) by 
inhibiting cysteine proteases such 
as procathepsin L [76]
(E)-3-(3-(3,5-di-tert-
butyl-4-hydroxyphenyl)
acryloyl)-4-
hydroxyquinolin-2(1H)-
one**
Synthetic ↓Intracellular amastigotes 
(1.3 μM) [86]
L. panamensis (E)-1-(4-chlorophenyl)-
3-(3-((7-chloroquinolin-
4-yl)amino)phenyl)
prop-2-en-1-one**
Synthetic ↓Amastigotes (0.79 μg/mL) [87]
*TGF-β, transforming growth factor beta; IL-10, interleukin-10.
**Been reviewed by de Mello and coworkers [88].
Table 3. 
Several chalcone derivatives with high activity and selectivity against Leishmania spp.
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the complex inflammatory responses that mediate and determine the appearance of 
clinical features and the severity degree.
Various investigations have been conducted and showed that several  chalcone 
(natural and synthetic) derivatives have high activity (IC50 < 10 μg/mL or 
IC50 < 5 μM) and selectivity against Leishmania parasites in vitro and in vivo. 
However, the mode of action and molecular target of these chalcone derivatives have 
not been well elucidated yet. Licochalcone A showed strong activity against L. major 
(IC50 = 2.4 μg/mL) by damaging ultrastructure of promastigote and amastigote mito-
chondria of the parasite selectively and disturbing its function as respiration organelle 
[73]. Several studies also showed that fumarate reductase [74], nucleoside hydrolase, 
dihydroorotate dehydrogenase, oligopeptidase B and methionyl-tRNA synthetase 
in L. major [75], cysteine proteases in L. infantum [76], and glycerol 3-phosphate 
dehydrogenase (G3PDH) of L. mexicana [75, 77] can be targeted to kill the parasite. 
Chalcone derivatives strongly inhibiting these enzymes showed high activity in killing 
the parasite (Table 3). When the sunscreen activity of chalcones is generated by their 
conjugated electronic system, the antimicrobial activity of chalcones is caused by the 
presence of halogen, methoxy, hydroxy, and other functional groups.
5. Rashes
5.1 Acne vulgaris
Acne vulgaris, one of multifactorial acute inflammatory diseases, affects the pilo-
sebaceous unit (hair follicles) in the skin. This disease is commonly found in the area 
with high-density pilosebaceous units (face, neck, upper chest, shoulders, and back) 
and characterized by the presence of seborrhea (excessive grease production), nonin-
flammatory lesions (open comedones/blackhead and closed comedones/whitehead), 
inflammatory lesions (papules and pustules), and various degrees of scarring [89].
Pathogenesis of acne involves the interplay between four main factors including 
hyperseborrhoea (excessive sebum production) mediated by certain androgens and 
alterations in sebum fatty acid composition, hyperkeratinization within the fol-
licle that lead to the formation keratin plug (microcomedone), pilosebaceous unit 
colonization by Cutibacterium acnes (aerotolerant anaerobic bacterium) colony, and 
the release of inflammatory mediators in response to the presence of Cutibacterium 
acnes [90]. It was shown that Staphylococcus epidermidis (facultative anaerobic bac-
terium) also had a beneficial role by limiting the colonialization of Cutibacterium 
acnes and inflammation [91].
Several chalcone derivatives exhibited anti-acne activity with mainly as antibac-
terial and anti-inflammatory agents. Licochalcone A as a potent anti-inflammatory 
agent [31] has been studied and combined with other active compounds in 
 several anti-acne formulations. Skin care formulation containing licochalcone A, 
L-carnitine, and 1,2-decanediol can reduce pustule lesions, popular lesions, total 
lesions, and sebum levels [92]. A combination of 0.1% adapalene gel and moisturizer 
containing licochalcone A, L-carnitine, and 1,2-decanediol also showed synergistic 
effect in reducing inflammatory lesions without interfering the efficacy of each 
active ingredient [93]. Another combination between 0.1% adapalene gel and 
moisturizer containing licochalcone A, glycolic acid, salicylic acid, and glucono-
lactone even showed better results than monotherapy using only adapalene [94]. 
Licochalcone A, in another report, had antibacterial activity against Cutibacterium 
acnes and inhibited Cutibacterium acnes-mediated NLRP3 (nucleotide-binding 
domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome 
activation in the skin [95].
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Antibacterial effects against Cutibacterium acnes have been shown by phlor-
etin, xanthohumol, panduratin A, isopanduratin A, and some chalcone deriva-
tives. Phloretin, a natural dihydrochalcone derivative, showed both antibacterial 
effects by inhibiting the growth of Cutibacterium acnes (MIC = 0.5 mg mL−1) 
by blocking the activity of KAS III [beta-ketoacyl-(acyl-carrier-protein) syn-
thase III] in Cutibacterium acnes and anti-inflammatory effect by attenuating 
COX-2 and PGE2 expressions and inhibiting c-Jun N-terminal kinases (JNK) via 
toll-like receptor 2 (TLR2)-mediated inflammatory signaling in Cutibacterium 
acnes-induced inflammation of the skin [96, 97]. Four natural chalcone deriva-
tives, xanthohumol isolated from Humulus lupulus L. (minimum inhibitory 
concentration/MIC = 0.003 mg mL−1) [98], panduratin A and isopanduratin A 
isolated from Kaempferia pandurata Roxb. (MICs = 0.002 and 0.004 mg mL−1) 
[99], and 2′,6′-dihydroxy-3′-methyl-4′-methoxydihydrochalcone isolated from 
Eucalyptus maculata (MIC = 0.002 mg mL−1), also exhibited antibacterial activity 
against Cutibacterium acnes [100]. Different mode of action was shown by two 
synthetic chalcone derivatives, 2,2′-dihydroxychalcone and 2′-hydroxy-2,3,5′-
trimethoxychalcone, to reduce sebum secretion and pore size on the skin [101].
5.2 Seborrheic dermatitis and dandruff
Seborrheic dermatitis is a skin illness mainly influencing skin area with high 
amounts of sebaceous glands (such as the face, scalp, central chest, and anogenital) 
and characterized with the presence of erythematous patches with superficial 
scaling. The mildest form of seborrheic dermatitis that only affects the scalp area 
with no overt inflammation is usually considered as dandruff or pityriasis capitis. 
In general, seborrheic dermatitis affects adolescents during puberty to adulthood; 
however, another form of this disease is considered as infantile seborrheic dermati-
tis affecting babies and young children [102].
The main mechanism triggering this disease remains unknown; however, it 
is probably caused by the imbalance of three factors: sebum oversecretion by the 
sebaceous gland that is affected by certain hormonal [103] and environmental [104] 
conditions, sebum metabolism by Malassezia spp. that accumulate linoleic acid, 
and individual susceptibility to the penetration of the unsaturated fatty acids that 
mediate pain and itch [105, 106]. The lipid layer of Malassezia spp. also stimulated 
keratinocytes to produce anti-inflammatory (IL-4, IL-10) and pro-inflammatory 
(IL-1α, IL-6, IL-8, IL-12, TNF-α) cytokines [107, 108].
Licochalcone A is an active anti-inflammatory drug used in several formula-
tions in treating seborrheic dermatitis. Tonic containing urea, lactate, polido-
canol, and licochalcone A-containing Glycyrrhiza inflate root extract improved 
dry, itchy, and inflamed scalp condition which is often associated with sebor-
rheic dermatitis. A combination of rinse-off shampoo (containing piroctone 
olamine and climbazole) and leave-on tonic (containing piroctone olamine 
and licochalcone A) significantly reduced dandruff and relieved its micro-
inflammation. Treatment using this combination also significantly decreased 
some cytokines including IL-1ra/IL-1α and IL-8, compared to placebo shampoo 
[109]. In another report, a moisturizer containing licochalcone 0.025% also had 
a comparable cure rate with hydrocortisone 1% moisturizer in treating infantile 
seborrheic dermatitis [110].
5.3 Psoriasis
Psoriasis is a multifactorial skin disease characterized by the presence of red, 
dry, itchy, and scaly plaques due to chronic hyperproliferative keratinocyte cells and 
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inflammatory cell infiltration [111]. Pathogenesis of this disease includes several 
steps triggered by environmental [111] and genetic [112] factors: (1) secretion of 
TNF-α by keratinocyte cells triggered by certain environmental and genetic factors, 
(2) TNF-α-induced dendritic cell activation and production of IL-23, (3) IL-23-
induced T-helper 17 (Th17) cell differentiation, and secretion of IL-17A that cause 
hyperproliferation of keratinocyte cells [113]. Moreover, IL-17A also synergizes with 
IL-36 secreted by keratinocytes to amplify and support chronic characteristic of this 
disease [114]. Several molecular targets have been identified with drug candidates 
being tested in clinical stages such as cytokines (TNF-α, IL-17A, IL-17E, IL-17F, and 
IL-23 p19 subunit), phosphodiesterase 4, A3 adenosine receptor, and Janus kinases 
(JAK1-JAK3) signaling pathways [115].
Recent studies report that chalcones are efficient in improving some psoriasis 
models. Intraperitoneal injection of isoliquiritigenin compound remedied mouse 
with psoriasis-like skin predisposition and decreased several pro-inflammatory 
cytokines (IL-6 and IL-8) as well by inhibition of NF-κB on in vitro and in vivo 
assays [116]. The isolated licochalcone B and echinatin compounds from Glycyrrhiza 
glabra also exhibited higher activity than isoliquiritigenin compound in relieving 
psoriasis-like inflammation induced by several pro-inflammatory agents such as 
12-O-tetradecanoylphorbal-13-acetate (TPA), adenosine diphosphate (ADP), and 
UVB radiation [117]. In other targets, several α-bromo- and α-tetrafluoromethyl-
2′,3,4,4′-tetramethoxychalcones showed anti-inflammatory and immunomodula-
tory activities through inhibition on IL-3 and interferon-α (IFNα)-induced JAK2/
STAT5 (signal transducer and activator of transcription 5) [118] and STAT1 and 
STAT2 [119] signaling pathways. Furthermore, both compounds were also able to 
inhibit NF-κB and to activate Nrf2 transcriptional activity [120].
5.4 Atopic dermatitis
Atopic dermatitis (atopic eczema) is a complex inflammatory skin disease char-
acterized by the presence of skin dryness with intense itching sensation, younger/
early-onset, and atopy [121]. There are three main factors that contribute to patho-
genesis of atopic dermatitis, i.e., (1) genetic and immune factors on the defect of 
physical and chemical barrier in the skin [122], (2) hyperactive immune cells due 
to a biological response (mutation on caspase recruitment domain family member 
11/CARD11 gene) because of the incoming pollutants and pathogens [123], and 
(3) environmental factors that contribute in triggering and enhancing severities of 
atopic dermatitis process [124].
Chalcone-containing formulations have been prepared and evaluated in 
treating atopic dermatitis. These chalcone derivatives were combined with other 
active ingredients, and it was found that they acted as anti-inflammatory and 
antioxidative agents. It was also reported that licochalcone A-containing moistur-
izer showed slightly lower effect than hydrocortisone lotion in treating mild-
to-moderate atopic dermatitis in children [125]. Another study also found that 
oil-in-water formulation containing Glycyrrhiza inflata root extract (licochalcone 
A), decanediol, menthoxypropanediol, and ω-6-fatty acids had quite similar effi-
cacy compared to hydrocortisone lotion (standard medication) in a 1-week clinical 
study with significant improvement in skin conditions, which is remarkable [126]. 
Using 0.02% triamcinolone acetonide cream as a reference, a combination of 
4-t-butylcyclohexanol and licochalcone A compounds in moisturizer formulation 
showed a slower improvement rate, but better result in relieving erythema and 
increasing skin hydration [127]. Meanwhile, water-in-oil emollient containing 
licochalcone A, ω-6-fatty acids, ceramide 3, and glycerol formulation could serve 
a preventing effect on reducing atopic dermatitis flares even after stopping the 
treatment [128].
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Other compounds such as isoliquiritigenin and 3′-isopentenyl-2,2′,4,4′-
tetrahydroxy-6′-methoxychalcone (ITC) showed similar effects on atopic derma-
titis skin. Evaluation of isoliquiritigenin in relieving atopic dermatitis-like lesion 
in mice caused a significant improvement in skin condition and attenuated several 
pro-inflammatory parameters such as Immunoglobulin E (IgE), Th2 cytokine 
upregulation, TNF-α, IL-6, and IL-4 [129]. ITC isolated from Sophora flavescens 
Aiton also ameliorated atopic dermatitis-like model in mice by inducing HO-1 
expression which leads to suppression of Th2 chemokine expressions [130].
6. Rosacea
Rosacea is a multifactorial chronic inflammatory skin disorder characterized 
by the presence of persistent or periodical redness and several kinds of changing 
in phymatous in the central facial skin (cheeks, chin, nose, and central part of 
forehead) [131]. Based on the appearance of certain major phenotypes, rosacea is 
divided into erythematotelangiectatic rosacea, papulopustular rosacea, glandular/
hyperplastic rosacea, ocular rosacea, and other special forms such as rosacea 
conglobata, rosacea fulminans, gram-negative rosacea, steroid-induced rosacea, 
granulomatous (lupoid) rosacea, Morbihan’s disease, and rosacea in children [132]. 
Pathogenesis of rosacea has not been fully comprehended yet, but there are several 
factors that involve including (1) genetics, Haber’s syndrome with rosacea as one of 
clinical feature can be inherited; (2) environment, certain environmental factors 
can trigger rosacea including extreme air temperature, sudden temperature changes, 
food (caffeine, alcohol, hot and spicy food), sunlight (UV and IR radiation), etc.; 
(3) overproduction of antimicrobial peptides (AMPs) by congenital immune system 
such as LL-37; (4) ROS-induced inflammation produced by adaptive immune cells; 
(5) overexpression of toll-like receptors (TLRs); (6) Demodex folliculorum-induced 
inflammations; and (7) neuroinflammation and vascular hyperactivity [132, 133].
Hesperidin methyl chalcone, licochalcone A, and tetracarboxymethyl naringenin 
chalcone exhibit significant activity in improving the skin with rosacea. Clinical stud-
ies showed that hesperidin methyl chalcone-containing topical formulations could 
improve infected skin condition by decreasing the proportion of dilated vessels, total 
vessel area, and IL8 productions. These formulations showed a complementary effect 
between each active ingredient in relieving inflammation and reducing the redness 
[134]. Another study reported that hesperidin methyl chalcone had anti-inflammatory 
and anti-analgesic activities which are two targets in treating rosacea by inhibiting 
transient receptor potential vanilloid type 1 (TRPV1), oxidative stress, TNF-α, inter-
leukin (IL) production (IL-1β, IL-6, and IL-10), and NF-κB activity [135].
Licochalcone A is a natural product from Glycyrrhiza inflate that shows potent 
activity in treating especially in mild and moderate symptoms. In vivo studies 
showed that skin care formulations containing licochalcone A provided various 
activities such as UVA/UVB protecting, moisturizing, and redness concealing abili-
ties that improved skin appearance with rosacea. These formulations exhibited high 
compatibility with sensitive skin and could be combined with other treatments such 
as metronidazole treatment [136]. Licochalcone A-containing moisturizer formula-
tion also increased skin hydration and reduced transepidermal water loss [137]. The 
most recent chalcone derivative used as anti-rosacea is a stabilized form of nar-
ingenin chalcone, i.e., tetracarboxymethyl naringenin chalcone (TNC). TNC was 
obtained from naringenin chalcone by total etherification reaction of methylchloro-
acetate. In vitro study showed that TNC significantly reduces LL-37, calcitriol, and 
several LL-37-induced inflammatory mediators in keratinocytes. Clinical test also 
showed that formulation containing TNC as a single active ingredient reduced the 
redness of the skin with rosacea compared to untreated skin areas [138].
Cosmetic Science - Formulation and Recent Advances
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7. Conclusions
Most of the skin diseases involve any defects in the skin due to its interaction 
with UV irradiation, pollutant, and/or other internal and external factors. Because 
of that, several skin diseases such as pigmentation disorders (melasma and vitiligo), 
cutaneous leishmaniasis, rashes (acne vulgaris, seborrheic dermatitis and dandruff, 
psoriasis, and atopic dermatitis), and rosacea have been reported and investigated 
for better medical treatment. Chalcones, a group of privileged molecules with 
1,3-diaryl-2-propen-1-one backbone, exhibit high efficacy in treating those skin 
diseases. These efficacies are strongly related to the good activity of chalcones as 
antioxidant, anti-inflammation and immunomodulation, anti-angiogenesis, antimi-
crobial agents, as well as their ability in modulating various enzymes. Even though 
chalcones are really potential to be used as a photoprotective agent, the utilization 
of designed synthetic chalcones is still limited due to their low photostability and 
medium to high toxicity and also because of unknown protein targets of those skin 
diseases as for today reports. Development in these fields is still required to obtain 
more potent drugs with excellent biocompatibility and other desired properties.
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